Merck & Co., Inc. (NYSE:MRK)'s talks to buy cancer-drug maker Seagen Inc. (NasdaqGS:SGEN) have stalled for now, threatening what would be the pharmaceutical giant's biggest deal in more than a decade, according to people familiar with the matter. The companies have so far failed to agree on a price, said the people, who asked not to be identified because the information was private. The talks could still resume and possibly yield an agreement, the people said.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
129 USD | -0.21% | +1.57% | +18.32% |
04:45pm | Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial | MT |
02:35pm | Redburn Atlantic Adjusts Price Target on Merck to $148 From $142 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.32% | 327B | |
+32.96% | 704B | |
+28.59% | 577B | |
-3.83% | 348B | |
+5.44% | 288B | |
+14.81% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.93% | 147B | |
-7.78% | 145B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck’s Reportedly Talks to Acquire Seagen Hit Snag, Threatening Mega Pharma Deal